Reponex Pharmaceuticals A/S is the subsidiary company of Pharma Equity Group. By repositioning Reponex finds new uses for active substances that are being used in other treatments. This means that the substances are used for other treatments than they were originally designated and registered for. The advantage of this is that the active substance’s basic toxicity and adverse effect profile are already known and described.

Repositioning has the potential to affect a significant number of patients, where there is currently an unmet medical need. When repositioned treatments result in an improved efficacy, safety and/or cost-saving effect both the patients and the drug developers reap from the benefits. Pharmaceutical companies can save both money and time in development by streamlining validation studies without the need to repeat human safety studies, giving patients faster access to new treatment paradigms aimed at treating their diseases.

Through the innovative reuse of existing knowledge, Reponex seeks to execute its clinical development programs to the fullest possible extent and thereby achieve low project risk. By combining effective drug development strategies, i.e. by repositioning in combination with a new route of administration, and in some cases by combination with various other active substances that act synergically on various aspects of the disease, the developments seek to achieve a potent therapeutic effect.